<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02879747</url>
  </required_header>
  <id_info>
    <org_study_id>NRA 6280003</org_study_id>
    <nct_id>NCT02879747</nct_id>
  </id_info>
  <brief_title>Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children</brief_title>
  <acronym>MAINTENANCE</acronym>
  <official_title>Individualizing the Dose of Growth Hormone (GH) to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children Within TR 98-0198-003</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective was to study whether normal growth velocity can be maintained with adapted GH
      dosage in GH treated prepubertal children who have responded to GH treatment with fulfilled
      catch up growth (=difference to target height reached, less than - 0.6 SDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the trial is to study the effect of adapted GH treatment in order to find an
      individualized GH dose maintaining normal growth velocity close to target height SDS and
      normal metabolism after fulfilled catch up growth in prepubertal children treated with
      individual doses of GH within the trail 98-0198-003 (1). The overall aim is to find for the
      individual the lowest effective GH dose during maintenance period, maintaining normal growth
      velocity and metabolism, i.e. a satisfacto1y biological active dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth velocity (defined as delta height SDS) from start to first year on adapted GH dosage in GH treated prepubertal children who have previously responded to GH treatment with fulfilled catch up growth.</measure>
    <time_frame>9 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in IGF-I and IGFBP-3</measure>
    <time_frame>start of study to one year after start</time_frame>
    <description>change in insulin-like growth factor I and its binding protein</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in body composition</measure>
    <time_frame>start of study to one year after start</time_frame>
    <description>Changes in muscle mass, bone mass and fat mass with DEXA technique</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>start of study to one year after start</time_frame>
    <description>measures of quality of Life with several validated questionaires</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Short Stature</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Unchanged dose Genotropin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>reduced dose 50% Genotropin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genotropin</intervention_name>
    <description>Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth</description>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_label>Interventional 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participated in the 'GH-dose catch-up study' 98- 0198-003.

          -  Midparental height reached (difference less than 0.6 SDS)

          -  Prepubertal at start of the study (girls =B 1, boys: testes :&lt;; 3ml).

          -  Signed written informed consent from the patient's parents (and the child if old
             enough)

        Exclusion Criteria:

          -  Disease affecting growth other than correctly treated hypothyroidism.

          -  Incapable of following the study protocol (i.e. bad compliance in the previous study).

          -  Puberty (&gt; breast stage 2, or testes &gt; 4ml).

          -  Poor compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berit Kriström, MD, Senior lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nils-Östen Nilsson, MD, Assoc Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Halmstad Department of Pediatrics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Halldin, MD, Senior consultant</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sten Ivarsson, MD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Malmö Academic Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Wikland KA, Kriström B, Rosberg S, Svensson B, Nierop AF. Validated multivariate models predicting the growth response to GH treatment in individual short children with a broad range in GH secretion capacities. Pediatr Res. 2000 Oct;48(4):475-84.</citation>
    <PMID>11004238</PMID>
  </reference>
  <results_reference>
    <citation>Kriström B, Aronson AS, Dahlgren J, Gustafsson J, Halldin M, Ivarsson SA, Nilsson NO, Svensson J, Tuvemo T, Albertsson-Wikland K. Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. J Clin Endocrinol Metab. 2009 Feb;94(2):483-90. doi: 10.1210/jc.2008-1503. Epub 2008 Nov 11.</citation>
    <PMID>19001519</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>December 29, 2017</last_update_submitted>
  <last_update_submitted_qc>December 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment</keyword>
  <keyword>growth hormone</keyword>
  <keyword>childhood</keyword>
  <keyword>short stature</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.gpgrc.gu.se</doc_url>
      <doc_comment>The document will be found under &quot;Trials&quot; and then &quot;GH-dose/Maintenance study&quot;</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>http://www.gpgrc.gu.se</doc_url>
      <doc_comment>The document will be found under &quot;Trials&quot; and then &quot;GH-dose/Maintenance study&quot;</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

